Market Cap
$2.0B
GENB
Generate Biomedicines, Inc.
$13.89 ▲ +0.65%
Prev close $13.80Market cap$2.0B
ConsensusStrong Buy
12-mo target$27.00 (+94.4%)
▲ Bullish
Analyst conviction 9/10
Insider Buying Cluster (5 insiders)High Impact Filing (7/10)12 New Institutional Positions4 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on GENB right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (92%)
Inst. Holders
50 funds
Inst. Value
$390.9M
Inst. Activity
12 buys / 4 sells
Insider Activity
$50.3M buy / $16.0K sell
Insider Net $
$50.3M
Social Sentiment
60° Warm
SEC Reports
5
Price chart 30d -14.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 fda
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation
Sep 1, 2026 Insider
ARNOLD FRANCES sold 1,000 shares
Director @ $16.00 ($16.0K)
Jun 30, 2026 Inst.
NORGES BANK — NEW
2,094,616 shares ($35.3M)
Jun 30, 2026 Inst.
May 7, 2026 SEC BlackRock, Inc. — NEW
1,659,966 shares ($28.0M)
Generate Biomedicines reported Q1 2026 collaboration revenue of $7.2M (down 18% YoY from $8.8M) and a net loss of $61.7M
8-K — Impact 6/10
Generate Biomedicines CEO Michael Nally led a $240,000 open-market share purchase, joined by three other executives in s
CLUSTER — Impact 7/10
Mar 4, 2026 Insider
Mar 2, 2026 SEC Nally Michael bought 20,000 shares
Chief Executive Officer @ $12.00 ($240.0K)
A cluster of insider transactions at Generate Biomedicines (GENB) over the past week includes two open-market purchases
CLUSTER — Impact 3/10
Analyst ratings buy % +4.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
92% rate it Buy or better · 12 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 8, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 28, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 14, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| May 8, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Apr 13, 2026 | HC Wainwright & Co. | INITIATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Aug 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Jul 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Jun 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Price targets
Where 5 covering analysts think GENB trades over the next 12 months.
$27.00 +94.4% upside Strong Buy
Current$13.89 Low$22.00 Median$27.00 High$30.00 5 analysts
$22.00$30.00
Analyst rating None as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
60°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 1 bullish, 2 bearish, 0 mixed, 2 neutral · avg impact 5.4/10.
BEARISH8-K6/10
Generate Biomedicines reported Q1 2026 collaboration revenue of $7.2M (down 18% YoY from $8.8M) and
May 7, 2026
BULLISHCLUSTER7/10
Generate Biomedicines CEO Michael Nally led a $240,000 open-market share purchase, joined by three o
Mar 6, 2026
NEUTRALCLUSTER3/10
A cluster of insider transactions at Generate Biomedicines (GENB) over the past week includes two op
Mar 2, 2026
BEARISH424B47/10
Generate Biomedicines is pricing its IPO of 25 million shares at $16.00 per share, raising $400 mill
Feb 27, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
fda
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical
Oct 1, 2026
short_volume
Short Volume: GENB — 68.0% short (0.4M / 0.6M)
Short: 374,279 | Exempt: 0 | TRF Vol: 550,562 | Short Ratio: 68.0% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: GENB — 65.2% short (0.3M / 0.5M)
Short: 347,640 | Exempt: 2,751 | TRF Vol: 532,891 | Short Ratio: 65.2% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: GENB — 60.3% short (0.4M / 0.6M)
Short: 365,967 | Exempt: 0 | TRF Vol: 607,359 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
short_volume
Short Volume: GENB — 64.5% short (0.3M / 0.5M)
Short: 344,637 | Exempt: 0 | TRF Vol: 534,061 | Short Ratio: 64.5% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.55 | $-0.67–$-0.44 | — | +0.0% | 1↑ 2↓ | $0.0B | 4 |
| Next Q | $-0.57 | $-0.63–$-0.44 | — | +0.0% | 1↑ 2↓ | $0.0B | 4 |
| Current FY | $-2.30 | $-2.50–$-2.14 | — | +0.0% | 2↑ 2↓ | $0.0B | 4 |
| Next FY | $-2.28 | $-2.72–$-1.53 | 0.9% | +0.0% | 0↑ 2↓ | $0.0B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.545 | — |
| 7d ago | $-0.545 | — |
| 30d ago | $-0.545 | — |
| 60d ago | $-0.540 | -0.005 |
| 90d ago | $-0.540 | -0.005 |
Institutional ownership
Which big funds own GENB (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $390.9M total value (23,166,326 shares) as of 2026-Q2. Top holders: FMR, Capital, NORGES. Net buying activity: 12 institutions added/increased vs 4 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 5,221,599 | $88.1M | 22.5% | NEW |
| Capital World Investors | 4,215,632 | $71.1M | 18.2% | NEW |
| NORGES BANK | 2,094,616 | $35.3M | 9.0% | NEW |
| BlackRock, Inc. | 1,659,966 | $28.0M | 7.2% | NEW |
| BAKER BROS. ADVISORS LP | 1,423,602 | $24.0M | 6.1% | NEW |
| JPMORGAN CHASE & CO | 1,409,649 | $23.8M | 6.1% | TRIM -52.2% |
| ARK Investment Management LLC | 1,284,617 | $21.7M | 5.5% | DOUBLED +157.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,132,750 | $19.1M | 4.9% | DOUBLED +762.6% |
| NVIDIA CORP | 833,325 | $14.1M | 3.6% | NEW |
| GEODE CAPITAL MANAGEMENT, LLC | 735,003 | $12.4M | 3.2% | DOUBLED +521.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 2,094,616 | — | $35.3M |
| BlackRock, Inc. | NEW | — | 1,659,966 | — | $28.0M |
| JPMORGAN CHASE & CO | TRIM | 2,947,259 | 1,409,649 | -52.2% | $23.8M |
| ARK Investment Management LLC | DOUBLED | 498,408 | 1,284,617 | +157.7% | $21.7M |
| VANGUARD CAPITAL MANAGEMENT LLC | DOUBLED | 131,319 | 1,132,750 | +762.6% | $19.1M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 118,243 | 735,003 | +521.6% | $12.4M |
| VANGUARD FIDUCIARY TRUST CO | DOUBLED | 17,456 | 175,356 | +904.6% | $3.0M |
| BARCLAYS PLC | ADD | 70,894 | 116,902 | +64.9% | $2.0M |
| BANK OF AMERICA CORP /DE/ | ADD | 34,196 | 55,430 | +62.1% | $935.1K |
| CITIGROUP INC | DOUBLED | 2,244 | 30,587 | +1263.1% | $516.0K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net $50.3M — $50.3M bought, $16.0K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | ARNOLD FRANCES | Director | SELL | 1,000 | $16.00 | $16.0K |
| Mar 4, 2026 | Nally Michael | Chief Executive Officer | BUY | 20,000 | $12.00 | $240.0K |
| Mar 2, 2026 | Silvers Jason | President & CFO | BUY | 1,000 | $16.00 | $16.0K |
| Mar 2, 2026 | AFEYAN NOUBAR | Director | CONVERT | 2,109,704 | — | — |
| Mar 2, 2026 | AFEYAN NOUBAR | Director | CONVERT | 2,777,752 | — | — |
| Mar 2, 2026 | Silvers Jason | President & CFO | BUY | 500 | $16.00 | $8.0K |
| Mar 2, 2026 | AFEYAN NOUBAR | Director | CONVERT | 12,723,940 | — | — |
| Mar 2, 2026 | AFEYAN NOUBAR | Director | CONVERT | 2,109,704 | — | — |
| Mar 2, 2026 | AFEYAN NOUBAR | Director | CONVERT | 13,702,224 | — | — |
| Mar 2, 2026 | AFEYAN NOUBAR | Director | CONVERT | 2,109,704 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for GENB.
Shares short
7,180,013
Settlement Sep 15, 2026
Change vs prior
-3.7%
Semi-monthly cycle
Days to cover
7.2
At avg daily volume
Of shares outstanding
≈5.6%
Estimate — not % of float
All GENB filing & press-release reports (5)
- 8-K reportMay 7, 2026
- CLUSTER reportMar 6, 2026
- CLUSTER reportMar 2, 2026
- 424B4 reportFeb 27, 2026
- EFFECT reportFeb 27, 2026